14-3-3 Isotypes Facilitate Coupling of Protein Kinase C-zeta to Raf-1: Negative Regulation by 14-3-3 Phosphorylation
Overview
Affiliations
14-3-3 Proteins may function as adapters or scaffold in signal-transduction pathways. We found previously that protein kinase C-zeta (PKC-zeta) can phosphorylate and activate Raf-1 in a signalling complex [van Dijk, Hilkmann and van Blitterswijk (1997) Biochem. J. 325, 303-307]. We report now that PKC-zeta-Raf-1 interaction is mediated by 14-3-3 proteins in vitro and in vivo. Co-immunoprecipitation experiments in COS cells revealed that complex formation between PKC-zeta and Raf-1 is mediated strongly by the 14-3-3beta and -theta; isotypes, but not by 14-3-3zeta. Far-Western blotting revealed that 14-3-3 binds PKC-zeta directly at its regulatory domain, where a S186A mutation in a putative 14-3-3-binding domain strongly reduced the binding and the complex formation with 14-3-3beta and Raf-1. Treatment of PKC-zeta with lambda protein phosphatase also reduced its binding to 14-3-3beta in vitro. Preincubation of an immobilized Raf-1 construct with 14-3-3beta facilitated PKC-zeta binding. Together, the results suggest that 14-3-3 binds both PKC-zeta (at phospho-Ser-186) and Raf-1 in a ternary complex. Complex formation was much stronger with a kinase-inactive PKC-zeta mutant than with wild-type PKC-zeta, supporting the idea that kinase activity leads to complex dissociation. 14-3-3beta and -θ were substrates for PKC-zeta, whereas 14-3-3zeta was not. Phosphorylation of 14-3-3beta by PKC-zeta negatively regulated their physical association. 14-3-3beta with its putative PKC-zeta phosphorylation sites mutated enhanced co-precipitation between PKC-zeta and Raf-1, suggesting that phosphorylation of 14-3-3 by PKC-zeta weakens the complex in vivo. We conclude that 14-3-3 facilitates coupling of PKC-zeta to Raf-1 in an isotype-specific and phosphorylation-dependent manner. We suggest that 14-3-3 is a transient mediator of Raf-1 phosphorylation and activation by PKC-zeta.
CRABP1-complexes in exosome secretion.
Nhieu J, Wei C, Ludwig M, Drake J, Wei L Cell Commun Signal. 2024; 22(1):381.
PMID: 39075476 PMC: 11285139. DOI: 10.1186/s12964-024-01749-w.
Breedy S, Ratnayake W, Lajmi L, Hill R, Acevedo-Duncan M Front Oncol. 2023; 13:1051516.
PMID: 36776326 PMC: 9910080. DOI: 10.3389/fonc.2023.1051516.
Cai N, Lou L, Al-Saadi N, Tetteh S, Runnels L J Biol Chem. 2018; 293(29):11491-11504.
PMID: 29866880 PMC: 6065181. DOI: 10.1074/jbc.RA118.001925.
Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model.
Germany C, Reker A, Hinton D, Oliveros A, Shen X, Andres-Beck L Proteomics. 2018; 18(7):e1700417.
PMID: 29437267 PMC: 6287941. DOI: 10.1002/pmic.201700417.
Walther C, Ferguson S Mol Endocrinol. 2015; 29(6):814-30.
PMID: 25942107 PMC: 5414738. DOI: 10.1210/me.2015-1091.